Novartis (NVS) Q4 2025 earnings review
Patent Cliff Strikes: Sales Stall, 2026 Profit Decline Guided
The long-awaited patent cliff has arrived. After a strong start to FY25, Novartis hit a wall in Q4: Net Sales declined 1% (cc) as US generic erosion for Entresto crushed the top line. While priority brands like Kisqali (+57%) and Pluvicto (+70%) are surging, they could not fully offset the 45% collapse in Entresto revenue during the quarter. Consequently, management guided for a 'low single-digit decline' in Core Operating Income for 2026, signaling a difficult transition year before growth potentially resumes.
🐂 Bull Case
Priority brands are delivering exceptional growth. Kisqali (+57% cc), Pluvicto (+70% cc), and Scemblix (+87% cc) prove the pipeline can eventually replace lost revenue. FDA approvals for Itvisma and Rhapsido add future layers of growth.
Despite the Q4 topline pressure, FY25 Core Operating Margin expanded +210bps to 40.1%. Management's focus on SG&A productivity is preserving profitability better than revenue trends suggest.
🐻 Bear Case
Guidance explicitly calls for Core Operating Income to decline in 2026. The 'gap year' caused by Entresto and Promacta generic entry is deeper than the 'stable' narrative implies.
Q4 Free Cash Flow collapsed 54% YoY to $1.66B. While FY FCF was up, the sudden Q4 drop indicates working capital or timing headwinds that coincide with the revenue slowdown.
⚖️ Verdict: ⚪
Neutral. The transition from legacy blockbusters to new growth drivers is executing well operationally, but the math is currently messy. With profits guided down for 2026 and Q4 sales turning negative, the stock faces a digestion period until the new portfolio fully overtakes the generic drag.
Key Themes
Entresto Cliff is Vertical, Not Gradual
The impact of US generic entry on Entresto was immediate and severe. Q4 sales for the brand plummeted 45% (cc) to $1.25B. This is a sharp reversal from the +22% growth seen in Q1 2025. This rapid erosion forces the rest of the portfolio to work much harder just to keep total revenue flat.
Oncology Portfolio Accelerating
Oncology is the clear savior of the P&L. Kisqali (+57% cc), Scemblix (+87% cc), and Pluvicto (+70% cc) are accelerating. Pluvicto's Q4 performance ($605M) validates the capacity expansion and pre-taxane launch strategy, moving past the supply constraints and adoption bottlenecks cited in early 2025.
Free Cash Flow Volatility
Q4 Free Cash Flow fell 54% to $1.7B, a significant deviation from the trend (FY FCF +8% to $17.6B). Management cited 'lower net cash flows from operating activities.' In a period of falling net income due to generics, cash conversion becomes critical; this drop warrants close monitoring to see if it's a timing mismatch or a structural change in working capital needs.
Aggressive Capital Returns
Novartis is using its balance sheet to bridge the growth gap. The company repurchased $8.9B in shares in 2025 and reduced share count by ~67M. A dividend increase of 5.7% (to CHF 3.70) signals confidence in long-term cash generation despite the 2026 earnings dip.
Pipeline Wins: Itvisma & Scemblix
R&D delivery remains high. Q4 saw FDA approval for Itvisma (gene therapy for SMA) and expanded indications for Scemblix (CML) and Pluvicto (mHSPC submission). These are not just scientific wins but necessary commercial offsets for 2026/2027.
Other KPIs
Stable (+0.7 pts cc). While the full year margin hit a robust 40.1%, Q4 margin compressed sequentially from Q3's ~39.3% and Q1's 42.1%. This reflects the loss of high-margin mature revenue (Entresto) and the mix shift toward launch-phase products requiring investment.
Decelerating. Derived from total sales minus other regions, US sales appear to have dropped significantly from the $6.0B run-rate seen in Q3 2025, driven entirely by the generic cliff. US revenue deduction adjustments also negatively impacted growth by 3 percentage points.
Reversing. Down 15% YoY (USD). Unlike Core figures which adjust for amortization and impairments, reported Net Income took a hit from higher income taxes and lower operating income, reflecting the cleaner reality of the generic impact.
Guidance
Decelerating. Down from +8% in FY25. This confirms that volume growth from new launches (Kisqali, Pluvicto) will barely outweigh the volume loss from Entresto/Promacta generics.
Reversing. A sharp pivot from the +14% growth delivered in FY25. This implies negative operating leverage: costs/investments for launches are rising while high-margin legacy revenue falls.
Key Questions
Bridge to 2027
With 2026 Core Operating Income guided to decline, precisely when in 2027 do you expect to crossover back to profitable growth? Is H1 2026 the trough?
FCF Disconnect
Free Cash Flow dropped 54% in Q4 despite Core OI being flat. Can you quantify how much of this was working capital timing versus a structural reduction in cash conversion due to the loss of mature, high-cash-margin products?
Entresto Erosion Velocity
Entresto sales fell 45% in Q4. Is this the steady-state erosion rate we should model for 2026, or was there channel destocking that exacerbated the drop?